Incubator Stock Review Initiates Coverage on Vystar
MWN-AI** Summary
On October 24, 2025, Vystar Corporation (OTCQB: VYST), based in Worcester, Massachusetts, announced that the Internet and Incubator Stock Review has initiated coverage of the company. This move highlights Vystar's commitment to support its portfolio of startups, empowering them to achieve profitability. Among its notable innovations is Vytex™, a refined latex product designed to eliminate allergens, making it suitable for various applications, including medical devices and consumer goods.
Vystar's focus on sustainability extends to its partnership with Corrie MacColl Global, aimed at enhancing market development and distribution. Moreover, Vystar's RxAir brand offers a patented UV-C light air purification system, capable of effectively neutralizing over 99.97% of airborne pathogens. The RxAir 400 model, recently adapted for consumer use, signifies a pivot towards broader market appeal amidst increasing health concerns.
Additionally, Vystar is investing in the future of collectibles through GoPaid.com, which aims to bridge cryptocurrency with the $62 billion collectible and fine art market. Anticipated to launch fully in Q4 2025, this platform seeks to democratize ownership through the tokenization of real-world assets, allowing investors to share in high-value collectibles. The review emphasizes the transformative potential of this approach, stating it could allow partial ownership in valuable items, enhancing liquidity for asset owners.
Overall, industry insights suggest that Vystar's innovative strategies, spanning sustainable products to cutting-edge air purification technology and blockchain integration, position it as a promising contender in emerging markets, with a potential impact reaching up to $16 trillion by 2030. For more detailed information, a full report is available for review on the Internet Stock Review website.
MWN-AI** Analysis
Vystar Corporation (OTCQB: VYST) has recently gained attention as the Internet and Incubator Stock Review initiated coverage on the company, highlighting its portfolio of innovative ventures poised for growth. Investors should consider a few key factors before engaging with Vystar stocks.
Firstly, Vystar is strategically positioning itself in high-demand markets with its flagship product, Vytex, a hypoallergenic rubber material suitable for various applications such as medical devices and consumer goods. This product’s unique properties reduce the risk of allergies while maintaining durability and flexibility, making it highly attractive to medical and commercial sectors. The partnership with Corrie MacColl Global for sustainable sourcing and distribution further enhances its market credibility, indicating Vystar’s commitment to quality and sustainability.
Additionally, the company’s commitment to innovative air purification technology through its RxAir products positions it favorably in public health contexts, especially given the heightened awareness of air quality and pathogen transmission post-COVID-19. This aligns well with current consumer trends towards health-conscious products.
Furthermore, Vystar's entry into the burgeoning field of crypto and collectibles via GoPaid.com is particularly intriguing. The anticipated tokenization of collectibles and fine art could democratize investing in high-value assets, potentially attracting a new class of investors to the company. This diversification not only broadens Vystar's revenue streams but also enhances its growth potential as it taps into the $62 billion collectibles market.
However, investors should remain cautious, as investing in small-cap and start-up companies often entails volatility and risk. With this in mind, thorough due diligence is advised. Overall, Vystar presents an appealing investment opportunity for those looking to participate in innovative, high-growth sectors while understanding the inherent risks involved.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Worcester, MA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Vystar ® Corporation (OTCQB: VYST) Vystar announced today the Internet and Incubator Stock Review has initiated coverage.
"We followed the team at Vystar over the past decade, as they assembled a portfolio of best-of-breed start-ups and companies. Vystar's goal has been to provide each of the companies with development assistance (management, corporate structuring and marketing) to the extent they could generate revenues and achieve profitability on a standalone basis."
Vystar has four start-ups under its umbrella, with the most recent addition GoPaid.com exhibiting breakthrough potential.
- Vystar’s Vytex ™ is a rubber hydrocarbon material with the proteins and non-rubber components that cause allergies removed to create an ultra-pure latex and dry rubber with a more compact molecular network of greater durability and flexibility that is virtually odor free with a reduced risk of developing or triggering contact allergies. Vytex is ideal for applications such as medical devices, catheters, tubing, condoms and gloves. Other products include foam mattresses, toppers, pillows, cushions, balloons, adhesives, sports equipment, footwear, apparel and threads. It is compatible with several synthetic rubbers which also enables their synergistic and symbiotic usage. Vystar has partnered with Corrie MacColl Global for sustainable sourcing, market development, manufacturing, sales & distribution. Vytex pillows, matresses and toppers are available at Vytex.com .
- RxAir promotes a healthy lifestyle with its innovative, patented UV-C light air purification technology. Independently tested by EPA- and FDA-certified laboratories, RxAir has been proven to destroy greater than 99.97% of airborne bacteria and viruses, including the flu, H1N1, multiple Coronavirus strains, pneumonia, MRSA, strep, TB, measles and the common cold.
RxAir 3000 model is well-known for its use in healthcare facilities and commercial businesses, RxAir was able to pivot its strategy to focus on its smaller, more consumer-friendly RxAir 400 model; highlighting how consumers can now get quality air filtration, traditionally found in operating rooms and surgical centers, in the comfort of their own homes – or their small business – providing a level of comfort much needed during these times.
FDA-cleared as a Class II medical device, the RxAir 400 covers up to 800 square feet, offering 15 different fan speeds. Its patented ‘kill chamber’ is where the magic happens, forcing the air around 3 powerful UV-C tubes for an extended period of time, ensuring the wavelength dosage needed to maximize the inactivation of viruses and bacteria.
- FEC - Fluid Energy Conversion (FEC) has taken a position as a global green energy company with a multitude of new technologies. We have an array of patented and soon-to-be patented technology that is destined to change energy production and energy usage in many arenas. Our independent research and development has focused on product solutions that harness stable vortex effects, cavitation and other unique fluid flow phenomena to move energy application into new chapters. Our main thrust is currently in water but other applications such as those in combustion are already being positioned as key concepts in those fields. For over 50 years, FEC’s chief scientist has developed and patented many successful inventions, both nationally and internationally, involving fluid mechanics, fluidics, thermodynamics and related physics. His experience has created a revolutionary extension of fluidic science that has led to patented products that are cost effective to manufacture, simple to understand, and they deliver an outstanding performance. Most of our technology does not require complicated processes or sophisticated electronics, making us truly unique.
- GoPaid.com - serves three main functions. First, we tokenize real-world collectables that can be traded on the blockchain. The collection GOPAID holds backs the company’s crypto currency as a (RWA) real-world asset. Occasionally we deaccession memorabilia’s of our collection making them available for sale. Lastly, we allow select large holders of GOPAID’s crypto currency to borrow items from the collection to display at their home’s, office or events.
" The Internet Stock Review stated, "What excites us most is their GoPaid.com Token portal, which has been under development since 2022 and is expected to launch fully in the 4th quarter. A BETA launch is anticipated in the next few weeks.”
The company is seeking to connect Crypto and Tokenization to the $62 billion domestic collectables and fine art market. In our opinion the tokenization of this market is game changing. It will for the first time, enable millions of investors to participate in the ownership of items which on an individual basis, range into the $10's of millions and out of the reach of most investors. Secondarily will enable the owners of these assets, for the first time, to sell partial ownership of their collectable or art, creating a partial liquidity event"
It further stated, "As illustration, the report highlighted the cash purchase of Claude Monet's Haystack, which was originally purchased for $2.3 million in 1986 and recently sold for $110.7 million. Had the work of art been tokenized in 1986, 100's if not 1,000's of investors could have participated. Additionally, had the ownership been in token form, the owner could have conceivably sold stake bringing in $10 million, as example, rather than having had to sell the masterpiece in its entirety."
"We are excited to initiate coverage and look forward to reporting on their launch and expansion into the collectable and art tokenization sector, which is estimated (all assets - equities, bonds, real estate, private assets and other financial instruments) to reach $16 trillion by 2030.
Investors can download or review the report https://internetstockreview.com/initiating-coverage-on-vystar-vyst/
About the Incubator and Internet Stock Review.
Roland Rick Perry, Managing Director of Institutional Analyst Inc. (IA), has been publishing investment newsletters since 1995, when he founded the firm.
Over the years, they have launched a series of industry-specific newsletters, including:
- Internet Stock Review (launched in 1998)
- Biotech Stock Review (2002)
- Beverage Stock Review (2015)
- Psychedelic Stock Review (2021)
These newsletters focus on small-cap companies across sectors like biotech, psychedelics, blockchain, beverages, and more, often highlighting what IA considers “best of breed” opportunities.
Institutional Analyst Inc. (IA), an independent investment research and investor relations firm, as well as editor of nine industry-specific investment reviews. Roland began his career on the floor of the Chicago Board Options Exchange (CBOE) as a runner in 1974. He later worked for a number of well-respected investment banking firms such as Merrill Lynch, Paine Webber, AG Becker Paribas, and Drexel Burnham Lambert, prior to launching his own firm in 1995. Phone (310) 594-8062 - The easiest way to reach us is to shoot us a text message.
The editorial staff can be reached via text or email @ (310) 594-8062
Internet | Biotech Stock Review
Psychedelic Stock Review
Email - roland@institutionalanalyst.com
LinkedIn
SeekingAlpha
Harvest Exchange
Stock Twits
Twitter
About Vystar Corporation:
Based in Worcester, Mass., Vystar ® Corp. (OTCQB: VYST) is the owner of RxAir ® UV light air purification products that destroy harmful airborne viruses and pathogens, Vytex ® Natural Rubber Latex (NRL), Partner/Investor of GOPAID.COM and Fluid Energy Solutions. Vytex is a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex for a stronger, more durable, yet environmentally safe, "green" and fully biodegradable product that can be used in a broad range of consumer and medical products. For more information, visit www.vystarcorp.com .
Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, product development and delivery, which may be provided by management, are also forward-looking statements as defined by the Act. Incubator Stock Review is paid by the company and outside third parties to create content and host and build websites over a 4-6 month period. Vystar does not edit or provide content, the author is independent. Vystar currently owns less than 10% GOPAID.com through a partnership agreement. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements. Investors should go to sec.gov website for Vystar’s various 10K, 10Q and other reports.
Follow us on social media and discount codes:
X formally Twitter: @ VystarCompany@ vytex
Contacts Vystar:
Media & Investors: Jamie Rotman, jrotman@vytex.com
Media, Investors or To Partner with Vystar, Company Phone Number: (508) 791-9114
FAQ**
How does Vystar Corp VYST plan to leverage its partnerships, such as with Corrie MacColl Global, to enhance the market development and sales of Vytex products in the competition-driven medical and consumer product industries?
What specific strategies does Vystar Corp VYST intend to implement to ensure the successful launch and user adoption of GoPaid.com's token portal, especially given its groundbreaking concept of tokenizing collectibles and fine art?
Considering the anticipated growth in the $62 billion collectibles market, how does Vystar Corp VYST differentiate itself from competitors in the art and collectibles tokenization space to attract investors and consumers?
With the RxAir product line targeting both healthcare and consumer markets, what customer feedback or data does Vystar Corp VYST have that demonstrates the effectiveness and market demand for its air purification technology?
**MWN-AI FAQ is based on asking OpenAI questions about Vystar Corp (OTC: VYST).
NASDAQ: VYST
VYST Trading
15.63% G/L:
$0.0614 Last:
250 Volume:
$0.0531 Open:



